Evox Therapeutics
June 16, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
Evox Therapeutics is an Oxford-based biotechnology company devoted to developing transformative therapeutics for neurological and neurodegenerative diseases by uniting engineered exosomes with next-generation genome editors.
Evox is advancing a focused pipeline of first-in-class therapeutics for genetically defined CNS disorders. Our lead ATXN2 programme for spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis is on track for CTA-enabling studies set to begin in 2026. A second programme targeting MSH3 for Huntington’s disease is progressing in parallel, and the modular nature of ExoEdit™ positions us to scale rapidly across additional repeat-expansion and monogenic indications.
Evox’s growth is funded by blue-chip investors, including Redmile, OrbiMed, GV, Invus, and Lilly, and reinforced by validating strategic partnerships.
Company HQ City:
Oxford
Company HQ State:
United Kingdom
Company HQ Country:
United Kingdom
Year Founded:
2016
Lead Product in Development:
Evox’s lead product is a CRISPR-based therapeutic targeting ATXN2, designed to treat spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS). The program is on track for candidate nomination in mid-2025, with CTA-enabling studies beginning in 2026
CEO
Per Lundin
Development Phase of Lead Product
Discovery
Number of Unlicensed Products Looking for Licensing
We have three programs for which we would seek partnerships
When you expect your next catalyst update?
Q3 NHP study
What is your next catalyst (value inflection) update?
Q3-Q4 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}